Cogstate (ASX:CGS): FY26 Results and 1QFY27 Clinical Trials Contract Update

Aditi Sarkar

26 October 2026 03:57 PM AEDT

Cogstate (ASX:CGS): FY26 Results and 1QFY27 Clinical Trials Contract Update

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Highlights

Cogstate (ASX:CGS) reported FY26 revenue of USD 60.86mn, up 14.6% YoY.
FY26 net profit after tax reached USD 11.9mn, up 17.3% YoY.
New sales contracts totalled USD 25.1mn during 1QFY27, following USD 89.0mn in FY26.
Contracted future revenue increased to USD 143.7mn at 30 September 2026.

Cogstate Limited develops digital cognitive assessment technology and provides clinical trial measurement services to pharmaceutical and biotechnology companies investigating neurological and psychiatric conditions. Cogstate (ASX:CGS) shares were quoted at AUD 3.45 on 26 October 2026, down 0.86% for the session. The company’s latest business update detailed new late-stage trial contracts and a larger contracted revenue position, following revenue and profit growth in FY26.

Company Business

Cogstate (ASX:CGS) operates in the measurement of cognition and central nervous system function. Its clinical trials business supplies digital tests, related scientific expertise, data quality processes and services used to assess participants in drug-development studies. Pharmaceutical sponsors employ these measures to collect consistent endpoint data across multiple trial sites and countries.

The company also develops cognitive assessment products for healthcare settings, where testing can help clinicians identify and monitor cognitive changes. Its technology is used across disease areas that include neurodegenerative disorders and psychiatric conditions. Trial work spans different development phases, with contracts recognised as services are delivered rather than when the agreements are signed.

Recent Development

In October 2026, Cogstate (ASX:CGS) reported USD 25.13mn of net sales contracts executed during 1QFY27, compared with USD 21.42mn in 1QFY26, an increase of approximately 17% YoY. Five Phase 3 studies in bipolar disorder or depression, involving two customers, accounted for more than 80% of the quarter’s contract value. These contracts broadened the company’s activity in mood-disorder research.

At 30 September 2026, contracted future revenue reached USD 143.7mn, compared with USD 118.5mn at 30 June 2026. The amount expected to be recognised during FY27 increased to USD 56.8mn from USD 48.3mn at the start of the financial year, while contracted FY28 revenue reached USD 39.7mn. The timing of revenue recognition depends on trial commencement, progress and the services required under individual contracts.

In its October annual general meeting materials, Cogstate (ASX:CGS) also reviewed FY26 contract activity and the transition into FY27. FY26 net sales contracts had totalled USD 89.0mn, compared with USD 41.26mn in FY25. The latest quarterly figures therefore follow a higher level of signed clinical trial work in the preceding financial year.

Financial Performance and Sector Context

Cogstate (ASX:CGS) reported FY26 revenue of USD 60.86mn, up 14.6% from approximately USD 53.1mn in FY25. Clinical trials revenue contributed USD 58.37mn, representing growth of 15.4% YoY. Net profit after tax increased 17.3% to USD 11.9mn, while profit before tax reached approximately USD 16.1mn. The company reported gross profit of approximately USD 35.4mn, equivalent to a gross margin near 58%.

The year-end cash balance was approximately USD 34.8mn, with no debt reported in the FY26 results presentation. The company’s contracted future revenue at 30 June 2026 was USD 118.5mn, up 32% from USD 90.0mn a year earlier. This balance represents work contracted for delivery over future periods; it is not the same measure as revenue recognised in the income statement.

Clinical trial services depend on research spending by drug developers, trial recruitment and protocol design. Larger Phase 3 programmes may run across several years, spreading contracted revenue across multiple reporting periods. Digital endpoint providers also face sponsor concentration, contracting cycles and competition for trial mandates.

Risks to Consider

Contract timing remains a business risk for Cogstate (ASX:CGS). Trial delays, cancellations or protocol amendments can change the pace of revenue recognition. A concentration of recent contracts among a small number of customers may increase exposure to individual sponsors. The cost of specialist staff, technology delivery and international operations can also influence margins. Contracted revenue does not eliminate the risk of subsequent modifications or delays.

What to Watch Next

For Cogstate (ASX:CGS), the next measurable developments include contract additions during 2QFY27, the rate at which signed work is converted into recognised revenue and progress on recently awarded Phase 3 studies. The company’s FY27 half-year results will provide an updated view of revenue, expenses, profitability and cash. Further disclosures on its clinical trial portfolio and healthcare product activity will also inform the operating picture.

Key Insights

Cogstate’s FY26 results recorded higher revenue and after-tax profit, alongside USD 89.0mn in signed contracts. The 1QFY27 update added USD 25.13mn in new contracts and increased total contracted future revenue to USD 143.7mn. Revenue conversion, contract concentration, study schedules and subsequent financial reporting remain the main points for monitoring.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.